MARKET

CNTA

CNTA

Centessa Pharmaceuticals Plc
NASDAQ
22.74
+0.06
+0.27%
Opening 12:12 01/07 EST
OPEN
22.70
PREV CLOSE
22.68
HIGH
23.69
LOW
22.70
VOLUME
298.57K
TURNOVER
--
52 WEEK HIGH
30.58
52 WEEK LOW
9.60
MARKET CAP
3.32B
P/E (TTM)
-12.4637
1D
5D
1M
3M
1Y
5Y
1D
Oppenheimer’s best small and mid-cap ideas for 2026
Seeking Alpha · 1d ago
Centessa Pharmaceuticals Enters Oversold Territory (CNTA)
NASDAQ · 2d ago
Centessa price target raised to $38 from $35 at Needham
TipRanks · 2d ago
5 Stock Picks Last Week From Wall Street's Most Accurate Analysts
Benzinga · 2d ago
Weekly Report: what happened at CNTA last week (1229-0102)?
Weekly Report · 2d ago
Centessa Pharmaceuticals Price Target Maintained With a $30.00/Share by Chardan Capital
Dow Jones · 5d ago
Centessa Pharmaceuticals Is Maintained at Buy by Chardan Capital
Dow Jones · 5d ago
3 ‘Strong Buy’ Stocks to Buy Now, 1/1/2026, According to Top Analysts
TipRanks · 6d ago
More
About CNTA
Centessa Pharmaceuticals plc is a clinical-stage pharmaceutical company. The Company is developing a new class of potential therapies within its orexin receptor 2 (OX2R) agonist program for the treatment of excessive daytime sleepiness (EDS), impaired attention, cognitive deficits, fatigue and other symptoms across neurological, neurodegenerative and neuropsychiatric disorders. It also has an early-stage immuno-oncology program focused on its LockBody technology platform. Its OX2R agonist pipeline includes ORX750, its advanced OX2R agonist development candidate, and ORX142, ORX489 and OX2R agonists in preclinical development. Its ORX750, an investigational, orally administered, highly potent and selective OX2R agonist, is in a Phase IIa study of participants with narcolepsy type 1 (NT1), NT2 and idiopathic hypersomnia (IH). ORX142 is the second OX2R agonist development candidate being advanced for the treatment of neurological and neurodegenerative disorders and other symptoms.

Webull offers Centessa Pharmaceuticals PLC - ADR stock information, including NASDAQ: CNTA real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, CNTA stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading CNTA stock methods without spending real money on the virtual paper trading platform.